Multimodal Imaging of Pancreatic Cancer Microenvironment in Response to an Antiglycolytic Drug

Abstract

AbstractLipid metabolism and glycolysis play crucial roles in the progression and metastasis of cancer, and the use of 3‐bromopyruvate (3‐BP) as an antiglycolytic agent has shown promise in killing pancreatic cancer cells. However, developing an effective strategy to avoid chemoresistance requires the ability to probe the interaction of cancer drugs with complex tumor‐associated microenvironments (TAMs). Unfortunately, no robust and multiplexed molecular imaging technology is currently available to analyze TAMs. In this study, the simultaneous profiling of three protein biomarkers using SERS nanotags and antibody‐functionalized nanoparticles in a syngeneic mouse model of pancreatic cancer (PC) is demonstrated. This allows for comprehensive information about biomarkers and TAM alterations before and after treatment. These multimodal imaging techniques include surface‐enhanced Raman spectroscopy (SERS), immunohistochemistry (IHC), polarized light microscopy, second harmonic generation (SHG) microscopy, fluorescence lifetime imaging microscopy (FLIM), and untargeted liquid chromatography and mass spectrometry (LC‐MS) analysis. The study reveals the efficacy of 3‐BP in treating pancreatic cancer and identifies drug treatment‐induced lipid species remodeling and associated pathways through bioinformatics analysis.